Celltrion held “Celltrion Science & Innovation Day 2025” last Friday at the Fairmont Hotel in Yeouido, Seoul, targeting Korean and international pharmaceutical and biotechnology analysts.

Celltrion said Monday that it organized the event to share the company's new drug development achievements, related strategies, and vision with professionals in the investment industry.

The event, themed around antibody-drug conjugates (ADCs), featured six individual sessions, including new drug development strategies, biobetter ADC development strategies and current status, and PBX-7016, a new camptothecin payload (a cell-toxic anticancer agent) for next-generation ADC development, among others.

In the first session, Kwon Ki-sung, Head of R&D at Celltrion, introduced the company's new drug development strategy and long-term plans, emphasizing that Celltrion is firmly establishing itself as a leader in new drug development. Kwon explained that the company is actively expanding its next-generation ADC pipeline, based on its accumulated antibody research and production platform over the past 20 years, and is securing promising technologies through open innovation as needed.

Lee Soo-young, head of New Drug Research, presented the company's ADC development strategy and current status, including the competitive landscape and differentiation strategies for each pipeline. Lee shared the research results and development speed of core new drug pipelines, including CT-P70, which is currently undergoing phase 1 clinical trials, CT-P71, and CT-P73, citing the indications, patient size, and unmet medical needs of each target as reasons for their high commercialization potential.

In addition to the three ADC pipelines highlighted on the day, Celltrion also revealed its sequential development plans for ‘Bispecific ADC,’ which targets dual targets, and ‘Dual-payload ADC,’ which maximizes therapeutic effects through payload combinations.

“It was an opportunity to clearly understand Celltrion's new drug development strategy,” said Yeo No-rae, a Hyundai Securities manager who attended the event. “We could hear specific explanations about areas that had previously been of interest in the market, which allowed us to firmly confirm the direction of Celltrion's ADC new drug development.”

The event featured presentations by Dr. Tae Han, a world-renowned authority in the ADC field and co-founder of ProfoundBio, as well as Jung Doo-young, CEO of Pinotbio, which is collaborating with Celltrion on joint development, Jimmy Li, CEO of Wuxi XDC, and Dr. Cho Byoung-chul, director of the Lung Cancer Center at Severance Hospital, who is participating in the CT-P70 clinical trial.

“By combining Celltrion's extensive experience and expertise in the antibody field with active collaboration, we are accelerating new drug development,” Celltrion CEO Seo Jin-seok said. “We will develop various new drugs that can provide better treatment options in areas with high unmet medical needs, including oncology, and drive rapid commercialization.”